Urinary Tract Cancer Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The urinary tract cancer market size has grown exponentially in recent years. It will grow from $3.21 billion in 2024 to $3.87 billion in 2025 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to advancements in diagnostics, pharmaceutical developments, awareness and early detection, precision medicine.

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $7.74 billion in 2029 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to immunotherapy advancements, telemedicine and remote monitoring, biomarker research, adjuvant therapies. Major trends in the forecast period include global collaboration, advances in palliative care, comprehensive survivorship programs, patient-centric care.

The anticipated rise in the prevalence of bladder cancer is set to fuel the growth of the urinary tract cancer market. Bladder cancer is characterized by the development of cancerous cells in the tissues of the urinary bladder, a crucial organ responsible for storing urine before its elimination from the body. This increased prevalence is leading to a greater demand for diagnostic tools, screening methods, and treatment options for individuals affected by urinary tract cancer. For example, in January 2023, a report by the American Cancer Society Inc., a U.S.-based cancer awareness organization, revealed an estimated increase in urinary system cancer cases to 168,560 in 2023, representing a 2.66% rise from 164,190 in 2022 in the United States. Additionally, cases of bladder cancer increased to 83,730 in 2021, a 2.8% increase from 81,400 in 2020. Hence, the growing prevalence of bladder cancer is expected to be a significant driver of the urinary tract cancer market's growth.

The increasing prevalence of urinary tract infections is anticipated to drive the expansion of the urinary tract cancer market in the future. Urinary tract infections result from bacterial infections that can affect various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment and management are required to prevent the spread of infection, which can potentially lead to cancer in multiple ways. For instance, as of January 2023, the National Institute of Health, a U.S.-based public health research agency, reported that urinary tract infections constituted the seventh most common reason for patients to visit an emergency department in the USA, with over 1 million visits annually. Of these cases, 22% (220,000) were classified as complicated UTIs, and approximately 100,000 patients were admitted each year. Hence, the rising prevalence of urinary tract infections is a driving force behind the growth of the urinary tract cancer market.

Leading companies operating in the urinary tract cancer market are increasingly focusing on advancing treatment methods to provide more effective and personalized solutions, gaining a competitive edge in the market. These advancements in urinary tract cancer treatment emphasize precise interventions, harnessing the body's immune system, improving surgical techniques, and tailoring treatments to meet the specific needs of individual patients. For example, in October 2022, UC San Diego Health, a U.S.-based healthcare system, introduced an advanced treatment for patients with low-grade upper tract urothelial cancer (LG-UTUC), a relatively uncommon subtype of urinary system cancer. This innovative treatment offers an alternative approach to the traditional complete kidney removal method, potentially sparing patients from the need for future dialysis or kidney transplants. The therapy involves the administration of Jelmyto, a drug containing mitomycin, a well-known chemotherapy agent, combined with a sterile hydrogel, delivered through guided injections that precisely target the tumor within the urinary system.

In August 2022, Merck & Co., a US-based pharmaceutical company, acquired Seagen for $40 billion. This acquisition allows Merck & Co. to expand its presence in oncology. Seagen Inc., a US-based biotechnology company, specializes in the development of various cancer treatments and drugs, including those for urinary tract cancer.

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Endo International PLC, Seagen Inc., Exelixis Inc., Ferring Pharmaceuticals, Bavarian Nordic, EUSA Pharma, UroGen Pharma Inc., Mersana Therapeutics, Protara Therapeutics Inc., Spectrum Pharmaceuticals, IDL Biotech AB, AroCell AB, ImmunityBio Inc.

North America was the largest region in the urinary tract cancer market in 2024. The regions covered in urinary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urinary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary tract cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgery and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary tract cancer market also includes sales of urinary catheters, cystoscopes, imaging equipment, urine cytology kits, pain relief medications and physical therapy devices which are used in providing diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

Urinary tract cancer encompasses malignancies that can develop in the kidneys, bladder, ureters, or urethra, often leading to symptoms like hematuria (blood in the urine) and pain. Taking preventive measures, such as quitting smoking, avoiding exposure to harmful substances, and promptly addressing urinary tract infections, can help reduce the risk of developing urinary tract cancer.

The primary types of urinary tract cancer include bladder cancer, urethral cancer, ureteric cancer, and renal pelvic cancer. Bladder cancer is characterized by abnormal cell growth in the lining of the bladder, directly affecting the urinary system, as the bladder plays a crucial role in this system. Treatments for bladder cancer typically involve approaches like radical cystectomy, radiation therapy, targeted therapy, chemotherapy, intravenous therapy, radiation therapy, and surgery. Diagnosis is typically conducted through methods such as cystoscopy, transurethral resection of the tumor, imaging tests, urine analyses, and various other techniques. Products for both treatment and diagnosis are distributed through channels such as retail pharmacies and online pharmacies.

The urinary tract cancer market research report is one of a series of new reports that provides urinary tract cancer market statistics, including urinary tract cancer industry global market size, regional shares, competitors with a urinary tract cancer market share, detailed urinary tract cancer market segments, market trends and opportunities and any further data you may need to thrive in the urinary tract cancer industry. This urinary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.